Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients

Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation

(2012) Masatsugu Hori et al.   CIRCULATION JOURNAL

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation

(2012) Takahiko Tanigawa et al.   Drug Metabolism and Pharmacokinetics

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

(2011) Valentin Fuster et al.   CIRCULATION

Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation

(2011) Hirotsugu Atarashi et al.   CIRCULATION JOURNAL

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

(2010)   AMERICAN HEART JOURNAL

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

(2010) Renato D. Lopes et al.   AMERICAN HEART JOURNAL

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

(2009) Xia Zhao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antithrombotic Therapy in Atrial Fibrillation

(2008) Daniel E. Singer et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry

(2008) G. Rohde   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES